NON-HS HISTIO-RELATED STUDIES
NLRC4 Mutation and XIAP Deficiency:
The Swiss-based company AB2 Bio is conducting a clinical study in North America (U.S.A. and Canada), and recruiting patients in several regions. The aim of this Phase III study is to assess the efficacy and safety of Tadekinig alfa in patients with monogenic, interleukin-18 driven autoinflammation caused by NLRC4-MAS mutation or XIAP deficiency.
If there is a study that you would like to see included on this page, it must be one that can be found on ClinicalTrials.gov. Please contact the Secretariat's office at email@example.com for more information.